{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:46:38Z","timestamp":1792169198804,"version":"4.4.0"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100012357","name":"LifeArc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012357","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,11,5]]},"DOI":"10.1038\/s41416-026-03533-8","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:12:11Z","timestamp":1783609931000},"page":"1376-1389","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Paediatric therapeutic development workshop on medulloblastoma"],"prefix":"10.1038","volume":"135","author":[{"given":"Claudia","family":"Montiel Equihua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2336-614X","authenticated-orcid":false,"given":"Joseph S.","family":"Baxter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"Molenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itziar","family":"Areso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Abbou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7509-3203","authenticated-orcid":false,"given":"John","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6786-4968","authenticated-orcid":false,"given":"Nicolas","family":"Andre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Ayrault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Daems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8365-9094","authenticated-orcid":false,"given":"Vicenzo","family":"D\u2019Angiolella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Danielson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam D.","family":"Durbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Fouladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar","family":"Gajjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7539-9472","authenticated-orcid":false,"given":"Richard","family":"Gilbertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Giraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Gottardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2756-5813","authenticated-orcid":false,"given":"Pamela","family":"Kearns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Kool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geffen","family":"Lass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5447-5322","authenticated-orcid":false,"given":"Stefan M.","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Rainsbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6557-895X","authenticated-orcid":false,"given":"Vijay","family":"Ramaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Straathof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik J.","family":"Swartling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Wechsler-Reya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8738-5913","authenticated-orcid":false,"given":"Andrew D. J.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jenkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Doz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4893-2184","authenticated-orcid":false,"given":"Steven C.","family":"Clifford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of LifeArc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Baxter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itziar","family":"Areso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geffen","family":"Lass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D. J.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jenkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Innovative Therapies for Children with Cancer (ITCC)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"Molenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Kearns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Cancer Research UK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Cancer Grand Challenge Protect team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Daems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"3533_CR1","doi-asserted-by":"publisher","unstructured":"Montiel Equihua C, Molenaar JJ, Areso I, Biegel JA, Blanc P, Chi SN et al. Paediatric therapeutic development workshop on rhabdoid tumours. Br J Cancer 2026. https:\/\/doi.org\/10.1038\/s41416-026-03348-7.","DOI":"10.1038\/s41416-026-03348-7"},{"key":"3533_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.semradonc.2009.09.005","volume":"20","author":"TE Merchant","year":"2010","unstructured":"Merchant TE, Pollack IF, Loeffler JS. Brain tumors across the age spectrum: biology, therapy, and late effects. Semin Radiat Oncol. 2010;20:58\u201366. https:\/\/doi.org\/10.1016\/j.semradonc.2009.09.005.","journal-title":"Semin Radiat Oncol"},{"key":"3533_CR3","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/neuonc\/noab200","volume":"23","author":"QT Ostrom","year":"2021","unstructured":"Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018. Neuro Oncol. 2021;23:iii1\u2013iii105. https:\/\/doi.org\/10.1093\/neuonc\/noab200.","journal-title":"Neuro Oncol"},{"key":"3533_CR4","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1007\/s00018-015-1930-2","volume":"72","author":"T Sun","year":"2015","unstructured":"Sun T, Plutynski A, Ward S, Rubin JB. An integrative view on sex differences in brain tumors. Cell Mol Life Sci. 2015;72:3323\u201342. https:\/\/doi.org\/10.1007\/s00018-015-1930-2.","journal-title":"Cell Mol Life Sci"},{"key":"3533_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.14791\/btrt.2022.0046","volume":"11","author":"JY Choi","year":"2023","unstructured":"Choi JY. Medulloblastoma: current perspectives and recent advances. Brain Tumor Res Treat. 2023;11:28\u201338. https:\/\/doi.org\/10.14791\/btrt.2022.0046.","journal-title":"Brain Tumor Res Treat"},{"key":"3533_CR6","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231\u201351. https:\/\/doi.org\/10.1093\/neuonc\/noab106.","journal-title":"Neuro Oncol"},{"key":"3533_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.2176\/nmc.ra.2016-0016","volume":"56","author":"N Kijima","year":"2016","unstructured":"Kijima N, Kanemura Y. Molecular classification of medulloblastoma. Neurol Med Chir. 2016;56:687\u201397. https:\/\/doi.org\/10.2176\/nmc.ra.2016-0016.","journal-title":"Neurol Med Chir"},{"key":"3533_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1470-2045(04)01424-X","volume":"5","author":"RJ Gilbertson","year":"2004","unstructured":"Gilbertson RJ. Medulloblastoma: signalling a change in treatment. Lancet Oncol. 2004;5:209\u201318. https:\/\/doi.org\/10.1016\/S1470-2045(04)01424-X.","journal-title":"Lancet Oncol"},{"key":"3533_CR9","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/nrc3410","volume":"12","author":"PA Northcott","year":"2012","unstructured":"Northcott PA, Jones DT, Kool M, Robinson GW, Gilbertson RJ, Cho YJ, et al. Medulloblastomics: the end of the beginning. Nat Rev Cancer. 2012;12:818\u201334. https:\/\/doi.org\/10.1038\/nrc3410.","journal-title":"Nat Rev Cancer"},{"key":"3533_CR10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00401-012-0958-8","volume":"123","author":"M Kool","year":"2012","unstructured":"Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, Northcott PA, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012;123:473\u201384. https:\/\/doi.org\/10.1007\/s00401-012-0958-8.","journal-title":"Acta Neuropathol"},{"key":"3533_CR11","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.ccell.2017.05.005","volume":"31","author":"FMG Cavalli","year":"2017","unstructured":"Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B, et al. Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell. 2017;31:737\u2013754.e6. https:\/\/doi.org\/10.1016\/j.ccell.2017.05.005.","journal-title":"Cancer Cell"},{"key":"3533_CR12","doi-asserted-by":"publisher","unstructured":"Bailey S, Jacobs S, Kourti M, Massimino EM, Andre N, Doz F, et al. Medulloblastoma therapy: Consensus treatment recommendations from SIOP-Europe and the European Reference Network. EJC Paediatr Oncol 2024;5. https:\/\/doi.org\/10.1016\/j.ejcped.2024.100205","DOI":"10.1016\/j.ejcped.2024.100205"},{"key":"3533_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-019-0063-6","volume":"5","author":"PA Northcott","year":"2019","unstructured":"Northcott PA, Robinson GW, Kratz CP, Mabbott DJ, Pomeroy SL, Clifford SC, et al. Medulloblastoma. Nat Rev Dis Prim. 2019;5:11 https:\/\/doi.org\/10.1038\/s41572-019-0063-6.","journal-title":"Nat Rev Dis Prim"},{"key":"3533_CR14","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/s41586-025-08973-5","volume":"642","author":"K Okonechnikov","year":"2025","unstructured":"Okonechnikov K, Joshi P, K\u00f6rber V, Rademacher A, Bortolomeazzi M, Mallm JP, et al. Oncogene aberrations drive medulloblastoma progression, not initiation. Nature. 2025;642:1062\u201372. https:\/\/doi.org\/10.1038\/s41586-025-08973-5.","journal-title":"Nature"},{"key":"3533_CR15","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00401-022-02464-x","volume":"144","author":"M Danilenko","year":"2022","unstructured":"Danilenko M, Zaka M, Keeling C, Crosier S, Lyman S, Finetti M, et al. Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development. Acta Neuropathol. 2022;144:565\u201378.","journal-title":"Acta Neuropathol"},{"key":"3533_CR16","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/nature09587","volume":"468","author":"P Gibson","year":"2010","unstructured":"Gibson P, Tong Y, Robinson G, Thompson MC, Currle DS, Eden C, et al. Subtypes of medulloblastoma have distinct developmental origins. Nature. 2010;468:1095\u20139. https:\/\/doi.org\/10.1038\/nature09587.","journal-title":"Nature"},{"key":"3533_CR17","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1038\/s41588-019-0531-7","volume":"51","author":"S Jessa","year":"2019","unstructured":"Jessa S, Blanchet-Cohen A, Krug B, Vladoiu M, Coutelier M, Faury D, et al. Stalled developmental programs at the root of pediatric brain tumors. Nat Genet. 2019;51:1702\u201313. https:\/\/doi.org\/10.1038\/s41588-019-0531-7.","journal-title":"Nat Genet"},{"key":"3533_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","volume":"7","author":"J Liu","year":"2022","unstructured":"Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, et al. Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022;7:3 https:\/\/doi.org\/10.1038\/s41392-021-00762-6. Published 2022 Jan 3.","journal-title":"Signal Transduct Target Ther"},{"key":"3533_CR19","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S1470-2045(18)30242-0","volume":"19","author":"SM Waszak","year":"2018","unstructured":"Waszak SM, Northcott PA, Buchhalter I, Robinson GW, Sutter C, Groebner S, et al. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol. 2018;19:785\u201398. https:\/\/doi.org\/10.1016\/S1470-2045(18)30242-0.","journal-title":"Lancet Oncol"},{"key":"3533_CR20","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/bpa.12017","volume":"23","author":"SE Lee","year":"2013","unstructured":"Lee SE, Lim SD, Kang SY, Suh SB, Suh YL. Prognostic significance of Ror2 and Wnt5a expression in medulloblastoma. Brain Pathol. 2013;23:445\u201353. https:\/\/doi.org\/10.1111\/bpa.12017.","journal-title":"Brain Pathol"},{"key":"3533_CR21","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.ccell.2016.03.002","volume":"29","author":"TN Phoenix","year":"2016","unstructured":"Phoenix TN, Patmore DM, Boop S, Boulos N, Jacus MO, Patel YT, et al. Medulloblastoma genotype dictates blood brain barrier phenotype. Cancer Cell. 2016;29:508\u201322. https:\/\/doi.org\/10.1016\/j.ccell.2016.03.002.","journal-title":"Cancer Cell"},{"key":"3533_CR22","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/s41586-022-05215-w","volume":"609","author":"LD Hendrikse","year":"2022","unstructured":"Hendrikse LD, Haldipur P, Saulnier O, Millman J, Sjoboen AH, Erickson AW, et al. Failure of human rhombic lip differentiation underlies medulloblastoma formation. Nature. 2022;609:1021\u20138. https:\/\/doi.org\/10.1038\/s41586-022-05215-w.","journal-title":"Nature"},{"key":"3533_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41586-019-1158-7","volume":"572","author":"MC Vladoiu","year":"2019","unstructured":"Vladoiu MC, El-Hamamy I, Donovan LK, Farooq H, Holgado BL, Sundaravadanam Y, et al. Childhood cerebellar tumours mirror conserved fetal transcriptional programs. Nature. 2019;572:67\u201373. https:\/\/doi.org\/10.1038\/s41586-019-1158-7.","journal-title":"Nature"},{"key":"3533_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41568-019-0223-8","volume":"20","author":"V Hovestadt","year":"2020","unstructured":"Hovestadt V, Ayrault O, Swartling FJ, Robinson GW, Pfister SM, Northcott PA. Medulloblastomics revisited: biological and clinical insights from thousands of patients. Nat Rev Cancer. 2020;20:42\u201356. https:\/\/doi.org\/10.1038\/s41568-019-0223-8.","journal-title":"Nat Rev Cancer"},{"key":"3533_CR25","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/cas.15691","volume":"114","author":"Y Funakoshi","year":"2023","unstructured":"Funakoshi Y, Sugihara Y, Uneda A, Nakashima T, Suzuki H. Recent advances in the molecular understanding of medulloblastoma. Cancer Sci. 2023;114:741\u20139. https:\/\/doi.org\/10.1111\/cas.15691.","journal-title":"Cancer Sci"},{"key":"3533_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21883-0","volume":"12","author":"P Skowron","year":"2021","unstructured":"Skowron P, Farooq H, Cavalli FMG, Morrissy AS, Ly M, Hendrikse LD, et al. The transcriptional landscape of Shh medulloblastoma. Nat Commun. 2021;12:1749. https:\/\/doi.org\/10.1038\/s41467-021-21883-0. Published 2021 Mar 19.","journal-title":"Nat Commun"},{"key":"3533_CR27","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1080\/14728222.2020.1823967","volume":"24","author":"L Lospinoso Severini","year":"2020","unstructured":"Lospinoso Severini L, Ghirga F, Bufalieri F, Quaglio D, Infante P, Di Marcotullio L. The SHH\/GLI signaling pathway: a therapeutic target for medulloblastoma. Expert Opin Ther Targets. 2020;24:1159\u201381. https:\/\/doi.org\/10.1080\/14728222.2020.1823967.","journal-title":"Expert Opin Ther Targets"},{"key":"3533_CR28","doi-asserted-by":"publisher","first-page":"69295","DOI":"10.18632\/oncotarget.20619","volume":"8","author":"GW Robinson","year":"2017","unstructured":"Robinson GW, Kaste SC, Chemaitilly W, Bowers DC, Laughton S, Smith A, et al. Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor. Oncotarget. 2017;8:69295\u2013302.","journal-title":"Oncotarget"},{"key":"3533_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111162","volume":"40","author":"D Williamson","year":"2022","unstructured":"Williamson D, Schwalbe EC, Hicks D, Aldinger KA, Lindsey JC, Crosier S, et al. Medulloblastoma group 3 and 4 tumors comprise a clinically and biologically significant expression continuum reflecting human cerebellar development. Cell Rep. 2022;40:111162. https:\/\/doi.org\/10.1016\/j.celrep.2022.111162.","journal-title":"Cell Rep"},{"key":"3533_CR30","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/s41586-022-05208-9","volume":"609","author":"KS Smith","year":"2022","unstructured":"Smith KS, Bihannic L, Gudenas BL, Haldipur P, Tao R, Gao Q, et al. Unified rhombic lip origins of group 3 and group 4 medulloblastoma. Nature. 2022;609:1012\u201320.","journal-title":"Nature"},{"key":"3533_CR31","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1200\/JCO.2013.50.9539","volume":"32","author":"DJ Shih","year":"2014","unstructured":"Shih DJ, Northcott PA, Remke M, Korshunov A, Ramaswamy V, Kool M, et al. Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol. 2014;32:886\u201396.","journal-title":"J Clin Oncol"},{"key":"3533_CR32","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00401-023-02566-0","volume":"145","author":"J Goddard","year":"2023","unstructured":"Goddard J, Castle J, Southworth E, Fletcher A, Crosier S, Martin-Guerrero I, et al. Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification. Acta Neuropathol. 2023;145:651\u201366.","journal-title":"Acta Neuropathol"},{"key":"3533_CR33","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nature13379","volume":"511","author":"PA Northcott","year":"2014","unstructured":"Northcott PA, Lee C, Zichner T, St\u00fctz AM, Erkek S, Kawauchi D, et al. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature. 2014;511:428\u201334. https:\/\/doi.org\/10.1038\/nature13379.","journal-title":"Nature"},{"key":"3533_CR34","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00401-011-0800-8","volume":"121","author":"DW Ellison","year":"2011","unstructured":"Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G, et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH\/WNT molecular subgroups. Acta Neuropathol. 2011;121:381\u201396. https:\/\/doi.org\/10.1007\/s00401-011-0800-8.","journal-title":"Acta Neuropathol"},{"key":"3533_CR35","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1093\/neuonc\/noae178","volume":"27","author":"EC Schwalbe","year":"2025","unstructured":"Schwalbe EC, Lindsey JC, Danilenko M, Hill RM, Crosier S, Ryan SL, et al. Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcomes: a multicenter cohort study. Neuro Oncol. 2025;27:222\u201336.","journal-title":"Neuro Oncol"},{"key":"3533_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.566822","volume":"10","author":"R Carta","year":"2020","unstructured":"Carta R, Del Baldo G, Miele E, Po A, Besharat ZM, Nazio F, et al. Cancer predisposition syndromes and medulloblastoma in the molecular era. Front Oncol. 2020;10:566822. https:\/\/doi.org\/10.3389\/fonc.2020.566822.","journal-title":"Front Oncol"},{"key":"3533_CR37","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.3390\/cancers15153889","volume":"15","author":"H Slika","year":"2023","unstructured":"Slika H, Alimonti P, Raj D, Caraway C, Alomari S, Jackson EM, et al. The neurodevelopmental and molecular landscape of medulloblastoma subgroups: current targets and the potential for combined therapies. Cancers. 2023;15:3889 https:\/\/doi.org\/10.3390\/cancers15153889.","journal-title":"Cancers"},{"key":"3533_CR38","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11060-006-9172-7","volume":"80","author":"P Zhang","year":"2006","unstructured":"Zhang P, Li H, Wu ML, Chen XY, Kong QY, Wang XW, et al. c-Myc downregulation: a critical molecular event in resveratrol-induced cell cycle arrest and apoptosis of human medulloblastoma cells. J Neurooncol. 2006;80:123\u201331. https:\/\/doi.org\/10.1007\/s11060-006-9172-7.","journal-title":"J Neurooncol"},{"key":"3533_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-10","volume":"9","author":"AO von Bueren","year":"2009","unstructured":"von Bueren AO, Shalaby T, Oehler-J\u00e4nne C, Arnold L, Stearns D, Eberhart CG, et al. RNA interference-mediated c-MYC inhibition prevents cell growth and decreases sensitivity to radio- and chemotherapy in childhood medulloblastoma cells. BMC Cancer. 2009;9:10. https:\/\/doi.org\/10.1186\/1471-2407-9-10.","journal-title":"BMC Cancer"},{"key":"3533_CR40","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1158\/1078-0432.CCR-13-2281","volume":"20","author":"P Bandopadhayay","year":"2014","unstructured":"Bandopadhayay P, Bergthold G, Nguyen B, Schubert S, Gholamin S, Tang Y, et al. BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res. 2014;20:912\u201325. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2281.","journal-title":"Clin Cancer Res"},{"key":"3533_CR41","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.18632\/oncotarget.2779","volume":"6","author":"F Wang","year":"2015","unstructured":"Wang F, Remke M, Bhat K, Wong ET, Zhou S, Ramaswamy V, et al. A microRNA-1280\/JAG2 network comprises a novel biological target in high-risk medulloblastoma. Oncotarget. 2015;6:2709\u201324. https:\/\/doi.org\/10.18632\/oncotarget.2779.","journal-title":"Oncotarget"},{"key":"3533_CR42","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1158\/1535-7163.MCT-19-0996","volume":"19","author":"NK Chaturvedi","year":"2020","unstructured":"Chaturvedi NK, Kling MJ, Griggs CN, Kesherwani V, Shukla M, McIntyre EM, et al. A novel combination approach targeting an enhanced protein synthesis pathway in MYC-driven (Group 3) medulloblastoma. Mol Cancer Ther. 2020;19:1351\u201362. https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-0996.","journal-title":"Mol Cancer Ther"},{"key":"3533_CR43","doi-asserted-by":"publisher","DOI":"10.1172\/JCI171136","volume":"134","author":"J Rodriguez-Blanco","year":"2024","unstructured":"Rodriguez-Blanco J, Salvador AD, Suter RK, Swiderska-Syn M, Palomo-Caturla I, et al. Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models. J Clin Invest. 2024;134:e171136. https:\/\/doi.org\/10.1172\/JCI171136.","journal-title":"J Clin Invest"},{"key":"3533_CR44","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-018-0008-7","volume":"3","author":"H Chen","year":"2018","unstructured":"Chen H, Liu H, Qing G. Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther. 2018;3:5 https:\/\/doi.org\/10.1038\/s41392-018-0008-7.","journal-title":"Signal Transduct Target Ther"},{"key":"3533_CR45","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","volume":"19","author":"R Dhanasekaran","year":"2022","unstructured":"Dhanasekaran R, Deutzmann A, Mahauad-Fernandez WD, Hansen AS, Gouw AM, Felsher DW. The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. Nat Rev Clin Oncol. 2022;19:23\u201336. https:\/\/doi.org\/10.1038\/s41571-021-00549-2.","journal-title":"Nat Rev Clin Oncol"},{"key":"3533_CR46","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.tips.2020.11.014","volume":"42","author":"DKH Thng","year":"2021","unstructured":"Thng DKH, Toh TB, Chow EK. Capitalizing on synthetic lethality of MYC to treat cancer in the digital age. Trends Pharm Sci. 2021;42:166\u201382. https:\/\/doi.org\/10.1016\/j.tips.2020.11.014.","journal-title":"Trends Pharm Sci"},{"key":"3533_CR47","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.15161","volume":"5","author":"F Lorenzin","year":"2016","unstructured":"Lorenzin F, Benary U, Baluapuri A, Walz S, Jung LA, von Eyss B, et al. Different promoter affinities account for specificity in MYC-dependent gene regulation. Elife. 2016;5:e15161. https:\/\/doi.org\/10.7554\/eLife.15161.","journal-title":"Elife"},{"key":"3533_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5632","volume":"5","author":"D Annibali","year":"2014","unstructured":"Annibali D, Whitfield JR, Favuzzi E, Jauset T, Serrano E, Cuartas I, et al. Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis. Nat Commun. 2014;5:4632. https:\/\/doi.org\/10.1038\/ncomms5632.","journal-title":"Nat Commun"},{"key":"3533_CR49","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/2051-5960-2-57","volume":"2","author":"RT Othman","year":"2014","unstructured":"Othman RT, Kimishi I, Bradshaw TD, Storer LC, Korshunov A, Pfister SM, et al. Overcoming multiple drug resistance mechanisms in medulloblastoma. Acta Neuropathol Commun. 2014;2:57 https:\/\/doi.org\/10.1186\/2051-5960-2-57.","journal-title":"Acta Neuropathol Commun"},{"key":"3533_CR50","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s11060-011-0756-5","volume":"107","author":"J Xu","year":"2012","unstructured":"Xu J, Erdreich-Epstein A, Gonzalez-Gomez I, Melendez EY, Smbatyan G, Moats RA, et al. Novel cell lines established from pediatric brain tumors. J Neurooncol. 2012;107:269\u201380. https:\/\/doi.org\/10.1007\/s11060-011-0756-5.","journal-title":"J Neurooncol"},{"key":"3533_CR51","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jbiotec.2016.07.028","volume":"236","author":"DP Ivanov","year":"2016","unstructured":"Ivanov DP, Coyle B, Walker DA, Grabowska AM. In vitro models of medulloblastoma: Choosing the right tool for the job. J Biotechnol. 2016;236:10\u201325. https:\/\/doi.org\/10.1016\/j.jbiotec.2016.07.028.","journal-title":"J Biotechnol"},{"key":"3533_CR52","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1089\/nat.2019.0831","volume":"30","author":"R Maeshima","year":"2020","unstructured":"Maeshima R, Moulding D, Stoker AW, Hart SL. MYCN Silencing by RNAi Induces Neurogenesis and Suppresses Proliferation in Models of Neuroblastoma with Resistance to Retinoic Acid. Nucleic Acid Ther. 2020;30:237\u201348. https:\/\/doi.org\/10.1089\/nat.2019.0831.","journal-title":"Nucleic Acid Ther"},{"key":"3533_CR53","doi-asserted-by":"publisher","first-page":"8902","DOI":"10.1080\/07391102.2022.2138977","volume":"41","author":"X Qin","year":"2023","unstructured":"Qin X, Chen B. Comprehensive analysis and validation reveal potential MYCN regulatory biomarkers associated with neuroblastoma prognosis. J Biomol Struct Dyn. 2023;41:8902\u201317. https:\/\/doi.org\/10.1080\/07391102.2022.2138977.","journal-title":"J Biomol Struct Dyn"},{"key":"3533_CR54","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1158\/0008-5472.CAN-09-2598","volume":"70","author":"L Chen","year":"2010","unstructured":"Chen L, Iraci N, Gherardi S, Gamble LD, Wood KM, Perini G, et al. p53 is a direct transcriptional target of MYCN in neuroblastoma. Cancer Res. 2010;70:1377\u201388. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-2598.","journal-title":"Cancer Res"},{"key":"3533_CR55","doi-asserted-by":"publisher","first-page":"5248","DOI":"10.3390\/cancers13205248","volume":"13","author":"S Sradhanjali","year":"2021","unstructured":"Sradhanjali S, Rout P, Tripathy D, Kaliki S, Rath S, Modak R, et al. The Oncogene MYCN Modulates Glycolytic and Invasive Genes to Enhance Cell Viability and Migration in Human Retinoblastoma. Cancers. 2021;13:5248 https:\/\/doi.org\/10.3390\/cancers13205248.","journal-title":"Cancers"},{"key":"3533_CR56","doi-asserted-by":"publisher","first-page":"8139","DOI":"10.1158\/0008-5472.CAN-05-2769","volume":"66","author":"L Chesler","year":"2006","unstructured":"Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, McMillan A, et al. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res. 2006;66:8139\u201346. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-2769.","journal-title":"Cancer Res"},{"key":"3533_CR57","doi-asserted-by":"publisher","first-page":"E1072","DOI":"10.1073\/pnas.1613091114","volume":"114","author":"FH Andrews","year":"2017","unstructured":"Andrews FH, Singh AR, Joshi S, Smith CA, Morales GA, Garlich JR, et al. Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis. Proc Natl Acad Sci USA. 2017;114:E1072\u2013E1080. https:\/\/doi.org\/10.1073\/pnas.1613091114.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3533_CR58","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ccell.2014.11.002","volume":"27","author":"RM Hill","year":"2015","unstructured":"Hill RM, Kuijper S, Lindsey JC, Petrie K, Schwalbe EC, Barker K, et al. Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. Cancer Cell. 2015;27:72\u201384.","journal-title":"Cancer Cell"},{"key":"3533_CR59","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ccell.2018.08.002","volume":"34","author":"A Forget","year":"2018","unstructured":"Forget A, Martignetti L, Puget S, Calzone L, Brabetz S, Picard D, et al. Aberrant ERBB4-SRC signaling as a hallmark of group 4 medulloblastoma revealed by integrative phosphoproteomic profiling. Cancer Cell. 2018;34:379\u2013395.e7. https:\/\/doi.org\/10.1016\/j.ccell.2018.08.002.","journal-title":"Cancer Cell"},{"key":"3533_CR60","doi-asserted-by":"publisher","first-page":"5987","DOI":"10.1158\/0008-5472.CAN-08-3660","volume":"69","author":"AH Sikkema","year":"2009","unstructured":"Sikkema AH, Diks SH, den Dunnen WF, ter Elst A, Scherpen FJ, Hoving EW, et al. Kinome profiling in pediatric brain tumors as a new approach for target discovery. Cancer Res. 2009;69:5987\u201395. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-3660.","journal-title":"Cancer Res"},{"key":"3533_CR61","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.canlet.2014.07.038","volume":"354","author":"W Petersen","year":"2014","unstructured":"Petersen W, Liu J, Yuan L, Zhang H, Schneiderjan M, Cho YJ, et al. Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283. Cancer Lett. 2014;354:68\u201376. https:\/\/doi.org\/10.1016\/j.canlet.2014.07.038.","journal-title":"Cancer Lett"},{"key":"3533_CR62","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1096\/fj.09-148593","volume":"24","author":"A Rossi","year":"2010","unstructured":"Rossi A, Schenone S, Angelucci A, Cozzi M, Caracciolo V, Pentimalli F, et al. New pyrazolo-[3,4-d]-pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells. FASEB J. 2010;24:2881\u201392.","journal-title":"FASEB J"},{"key":"3533_CR63","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1021\/acs.jmedchem.0c01511","volume":"64","author":"Z Xie","year":"2021","unstructured":"Xie Z, Yang X, Duan Y, Han J, Liao CJ. Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. Med Chem. 2021;64:1283\u2013345.","journal-title":"Med Chem"},{"key":"3533_CR64","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1242\/dev.01107","volume":"131","author":"E Puelles","year":"2004","unstructured":"Puelles E, Annino A, Tuorto F, Usiello A, Acampora D, Czerny T, et al. Otx2 regulates the extent, identity and fate of neuronal progenitor domains in the ventral midbrain. Development. 2004;131:2037\u201348. https:\/\/doi.org\/10.1242\/dev.01107.","journal-title":"Development"},{"key":"3533_CR65","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1158\/0008-5472.CAN-09-2331","volume":"70","author":"DC Adamson","year":"2010","unstructured":"Adamson DC, Shi Q, Wortham M, Northcott PA, Di C, Duncan CG, et al. OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. Cancer Res. 2010;70:181\u201391. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-2331.","journal-title":"Cancer Res"},{"key":"3533_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-018-0070-6","volume":"7","author":"S El Nagar","year":"2018","unstructured":"El Nagar S, Chakroun A, Le Greneur C, Figarella-Branger D, Di Meglio T, Lamonerie T, et al. Otx2 promotes granule cell precursor proliferation and Shh-dependent medulloblastoma maintenance in vivo. Oncogenesis. 2018;7:60. https:\/\/doi.org\/10.1038\/s41389-018-0070-6.","journal-title":"Oncogenesis"},{"key":"3533_CR67","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1038\/sj.onc.1208567","volume":"24","author":"H Kimura","year":"2005","unstructured":"Kimura H, Stephen D, Joyner A, Curran T. Gli1 is important for medulloblastoma formation in Ptc1+\/- mice. Oncogene. 2005;24:4026\u201336. https:\/\/doi.org\/10.1038\/sj.onc.1208567.","journal-title":"Oncogene"},{"key":"3533_CR68","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ccr.2004.08.019","volume":"6","author":"JT Romer","year":"2004","unstructured":"Romer JT, Kimura H, Magdaleno S, Sasai K, Fuller C, Baines H, et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+\/-)p53(-\/-) mice. Cancer Cell. 2004;6:229\u201340. https:\/\/doi.org\/10.1016\/j.ccr.2004.08.019.","journal-title":"Cancer Cell"},{"key":"3533_CR69","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.050323","volume":"17","author":"MJ van Essen","year":"2024","unstructured":"van Essen MJ, Apsley EJ, Riepsaame J, Xu R, Northcott PA, Cowley SA, et al. PTCH1-mutant human cerebellar organoids exhibit altered neural development and recapitulate early medulloblastoma tumorigenesis. Dis Model Mech. 2024;17:dmm050323. https:\/\/doi.org\/10.1242\/dmm.050323.","journal-title":"Dis Model Mech"},{"key":"3533_CR70","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.3390\/cells11162523","volume":"11","author":"C Suchors","year":"2022","unstructured":"Suchors C, Kim J. Canonical Hedgehog pathway and noncanonical GLI transcription factor activation in cancer. Cells. 2022;11:2523 https:\/\/doi.org\/10.3390\/cells11162523.","journal-title":"Cells"},{"key":"3533_CR71","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1097\/NEN.0b013e31821b94db","volume":"70","author":"P Buczkowicz","year":"2011","unstructured":"Buczkowicz P, Ma J, Hawkins C. GLI2 is a potential therapeutic target in pediatric medulloblastoma. J Neuropathol Exp Neurol. 2011;70:430\u20137. https:\/\/doi.org\/10.1097\/NEN.0b013e31821b94db.","journal-title":"J Neuropathol Exp Neurol"},{"key":"3533_CR72","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.canlet.2020.11.028","volume":"499","author":"P Infante","year":"2021","unstructured":"Infante P, Malfanti A, Quaglio D, Balducci S, De Martin S, Bufalieri F, et al. Glabrescione B delivery by self-assembling micelles efficiently inhibits tumor growth in preclinical models of Hedgehog-dependent medulloblastoma. Cancer Lett. 2021;499:220\u201331. https:\/\/doi.org\/10.1016\/j.canlet.2020.11.028.","journal-title":"Cancer Lett"},{"key":"3533_CR73","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1158\/1535-7163.MCT-11-0341","volume":"11","author":"V Chenna","year":"2012","unstructured":"Chenna V, Hu C, Pramanik D, Aftab BT, Karikari C, Campbell NR, et al. A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists. Mol Cancer Ther. 2012;11:165\u201373. https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-0341.","journal-title":"Mol Cancer Ther"},{"key":"3533_CR74","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1007\/s00432-016-2241-1","volume":"142","author":"Z Lin","year":"2016","unstructured":"Lin Z, Li S, Sheng H, Cai M, Ma LY, Hu L, et al. Suppression of GLI sensitizes medulloblastoma cells to mitochondria-mediated apoptosis. J Cancer Res Clin Oncol. 2016;142:2469\u201378. https:\/\/doi.org\/10.1007\/s00432-016-2241-1.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3533_CR75","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/nature14957","volume":"526","author":"J Samanta","year":"2015","unstructured":"Samanta J, Grund EM, Silva HM, Lafaille JJ, Fishell G, Salzer JL. Inhibition of Gli1 mobilizes endogenous neural stem cells for remyelination. Nature. 2015;526:448\u201352. https:\/\/doi.org\/10.1038\/nature14957.","journal-title":"Nature"},{"key":"3533_CR76","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1158\/1535-7163.MCT-20-0394","volume":"20","author":"G Vassal","year":"2021","unstructured":"Vassal G, Houghton PJ, Pfister SM, Smith MA, Caron HN, Li XN, et al. International consensus on minimum preclinical testing requirements for the development of innovative therapies for children and adolescents with cancer. Mol Cancer Ther. 2021;20:1462\u20138. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0394.","journal-title":"Mol Cancer Ther"},{"key":"3533_CR77","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejca.2020.01.027","volume":"130","author":"NA Schubert","year":"2020","unstructured":"Schubert NA, Lowery CD, Bergthold G, Koster J, Eleveld TF, Rodr\u00edguez A, et al. Systematic target actionability reviews of preclinical proof-of-concept papers to match targeted drugs to paediatric cancers. Eur J Cancer. 2020;130:168\u201381. https:\/\/doi.org\/10.1016\/j.ejca.2020.01.027.","journal-title":"Eur J Cancer"},{"key":"3533_CR78","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s43018-022-00509-4","volume":"4","author":"V Thatikonda","year":"2023","unstructured":"Thatikonda V, Islam SMA, Autry RJ, Jones BC, Gr\u00f6bner SN, Warsow G, et al. Comprehensive analysis of mutational signatures reveals distinct patterns and molecular processes across 27 pediatric cancers. Nat Cancer. 2023;4:276\u201389. https:\/\/doi.org\/10.1038\/s43018-022-00509-4.","journal-title":"Nat Cancer"},{"key":"3533_CR79","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ejca.2022.03.012","volume":"170","author":"MD Thakur","year":"2022","unstructured":"Thakur MD, Franz CJ, Brennan L, Brouwer-Visser J, Tam R, et al. Immune contexture of paediatric cancers. Eur J Cancer. 2022;170:179\u201393. https:\/\/doi.org\/10.1016\/j.ejca.2022.03.012.","journal-title":"Eur J Cancer"},{"key":"3533_CR80","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3389\/fonc.2020.01000","volume":"10","author":"B Nazha","year":"2020","unstructured":"Nazha B, Inal C, Owonikoko TK. Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy. Front Oncol. 2020;10:1000 https:\/\/doi.org\/10.3389\/fonc.2020.01000.","journal-title":"Front Oncol"},{"key":"3533_CR81","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1158\/1078-0432.CCR-23-1880","volume":"30","author":"R Ciccone","year":"2024","unstructured":"Ciccone R, Quintarelli C, Camera A, Pezzella M, Caruso S, Manni S, et al. GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma. Clin Cancer Res. 2024;30:2545\u201357. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1880.","journal-title":"Clin Cancer Res"},{"key":"3533_CR82","unstructured":"GD2-CAR T Cells for Pediatric Brain Tumours. https:\/\/clinicaltrials.gov\/study\/NCT05298995 (Accessed 12 December 2025)"},{"key":"3533_CR83","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41423-023-01019-8","volume":"20","author":"MC Pulanco","year":"2023","unstructured":"Pulanco MC, Madsen AT, Tanwar A, Corrigan DT, Zang X. Recent advancements in the B7\/CD28 immune checkpoint families: new biology and clinical therapeutic strategies. Cell Mol Immunol. 2023;20:694\u2013713. https:\/\/doi.org\/10.1038\/s41423-023-01019-8.","journal-title":"Cell Mol Immunol"},{"key":"3533_CR84","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1007\/s12094-021-02762-y","volume":"24","author":"S Li","year":"2022","unstructured":"Li S, Poolen GC, van Vliet LC, Schipper JG, Broekhuizen R, Monnikhof M, et al. Pediatric medulloblastoma express immune checkpoint B7-H3. Clin Transl Oncol. 2022;24:1204\u20138. https:\/\/doi.org\/10.1007\/s12094-021-02762-y.","journal-title":"Clin Transl Oncol"},{"key":"3533_CR85","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13000-025-01645-y","volume":"20","author":"P Font\u00e3o","year":"2025","unstructured":"Font\u00e3o P, Teixeira GR, Moreno DA, Marques RF, Stavale JN, Malheiros SMF, et al. High B7-H3 protein expression in Medulloblastoma is associated with metastasis and unfavorable patient outcomes. Diagn Pathol. 2025;20:49 https:\/\/doi.org\/10.1186\/s13000-025-01645-y.","journal-title":"Diagn Pathol"},{"key":"3533_CR86","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res. 2019;25:2560\u201374. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0432.","journal-title":"Clin Cancer Res"},{"key":"3533_CR87","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11060-022-04235-w","volume":"162","author":"KR Tringale","year":"2023","unstructured":"Tringale KR, Wolden SL, Karajannis M, Haque S, Pasquini L, Yildirim O, et al. Outcomes of intraventricular 131-I-omburtamab and external beam radiotherapy in patients with recurrent medulloblastoma and ependymoma. J Neurooncol. 2023;162:69\u201378. https:\/\/doi.org\/10.1007\/s11060-022-04235-w.","journal-title":"J Neurooncol"},{"key":"3533_CR88","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1200\/JCO.23.02229","volume":"42","author":"N Pinto","year":"2024","unstructured":"Pinto N, Albert CM, Taylor MR, Ullom HB, Wilson AL, Huang W, et al. STRIvE-02: a first-in-human phase I study of systemically administered B7-H3 chimeric antigen receptor T cells for patients with relapsed\/refractory solid tumors. J Clin Oncol. 2024;42:4163\u201372. https:\/\/doi.org\/10.1200\/JCO.23.02229.","journal-title":"J Clin Oncol"},{"key":"3533_CR89","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","volume":"13","author":"NA Vitanza","year":"2023","unstructured":"Vitanza NA, Wilson AL, Huang W, Seidel K, Brown C, Gustafson JA, et al. Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety. Cancer Discov. 2023;13:114\u201331. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0750.","journal-title":"Cancer Discov"},{"key":"3533_CR90","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","volume":"26","author":"MM Moasser","year":"2007","unstructured":"Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26:6469\u201387. https:\/\/doi.org\/10.1038\/sj.onc.1210477.","journal-title":"Oncogene"},{"key":"3533_CR91","first-page":"3272","volume":"57","author":"RJ Gilbertson","year":"1997","unstructured":"Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res. 1997;57:3272\u201380.","journal-title":"Cancer Res"},{"key":"3533_CR92","first-page":"3932","volume":"58","author":"RJ Gilbertson","year":"1998","unstructured":"Gilbertson RJ, Clifford SC, MacMeekin W, Meekin W, Wright C, Perry RH, et al. Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma. Cancer Res. 1998;58:3932\u20134.","journal-title":"Cancer Res"},{"key":"3533_CR93","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29316","volume":"69","author":"P Varlet","year":"2022","unstructured":"Varlet P, Bouffet E, Casanova M, Giangaspero F, Antonelli M, Hargrave D, et al. Comprehensive analysis of the ErbB receptor family in pediatric nervous system tumors and rhabdomyosarcoma. Pediatr Blood Cancer. 2022;69:e29316. https:\/\/doi.org\/10.1002\/pbc.29316.","journal-title":"Pediatr Blood Cancer"},{"key":"3533_CR94","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1200\/OP-25-00129","volume":"22","author":"E Nicol\u00f2","year":"2026","unstructured":"Nicol\u00f2 E, Gianni C, Tarantino P. Redefining human epidermal growth factor receptor 2 testing in breast cancer in the era of novel antibody-drug conjugates. JCO Oncol Pr. 2026;22:36\u201350.","journal-title":"JCO Oncol Pr"},{"key":"3533_CR95","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40425-018-0340-z","volume":"6","author":"A Nellan","year":"2018","unstructured":"Nellan A, Rota C, Majzner R, Lester-McCully CM, Griesinger AM, Mulcahy Levy JM, et al. Durable regression of medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. J Immunother Cancer. 2018;6:30 https:\/\/doi.org\/10.1186\/s40425-018-0340-z.","journal-title":"J Immunother Cancer"},{"key":"3533_CR96","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","volume":"3","author":"N Ahmed","year":"2017","unstructured":"Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, et al. HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol. 2017;3:1094\u2013101. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0184.","journal-title":"JAMA Oncol"},{"key":"3533_CR97","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s43018-024-00749-6","volume":"5","author":"M Hegde","year":"2024","unstructured":"Hegde M, Navai S, DeRenzo C, Joseph SK, Sanber K, Wu M, et al. Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat Cancer. 2024;5:880\u201394.","journal-title":"Nat Cancer"},{"key":"3533_CR98","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","volume":"27","author":"NA Vitanza","year":"2021","unstructured":"Vitanza NA, Johnson AJ, Wilson AL, Brown C, Yokoyama JK, K\u00fcnkele A, et al. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nat Med. 2021;27:1544\u201352. https:\/\/doi.org\/10.1038\/s41591-021-01404-8.","journal-title":"Nat Med"},{"key":"3533_CR99","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/s41586-022-04439-0","volume":"603","author":"E Seung","year":"2022","unstructured":"Seung E, Xing Z, Wu L, Rao E, Cortez-Retamozo V, Ospina B, et al. A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells. Nature. 2022;603:328\u201334. https:\/\/doi.org\/10.1038\/s41586-022-04439-0.","journal-title":"Nature"},{"key":"3533_CR100","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1038\/s41388-021-01714-8","volume":"40","author":"K Wilson","year":"2021","unstructured":"Wilson K, Shiuan E, Brantley-Sieders DM. Oncogenic functions and therapeutic targeting of EphA2 in cancer. Oncogene. 2021;40:2483\u201395. https:\/\/doi.org\/10.1038\/s41388-021-01714-8.","journal-title":"Oncogene"},{"key":"3533_CR101","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s41591-020-0827-2","volume":"26","author":"LK Donovan","year":"2020","unstructured":"Donovan LK, Delaidelli A, Joseph SK, Bielamowicz K, Fousek K, Holgado BL, et al. Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat Med. 2020;26:720\u201331. https:\/\/doi.org\/10.1038\/s41591-020-0827-2.","journal-title":"Nat Med"},{"key":"3533_CR102","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/mt.2012.210","volume":"21","author":"KK Chow","year":"2013","unstructured":"Chow KK, Naik S, Kakarla S, Brawley VS, Shaffer DR, Yi Z, et al. T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther. 2013;21:629\u201337. https:\/\/doi.org\/10.1038\/mt.2012.210.","journal-title":"Mol Ther"},{"key":"3533_CR103","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s10637-012-9801-2","volume":"31","author":"CM Annunziata","year":"2013","unstructured":"Annunziata CM, Kohn EC, LoRusso P, Houston ND, Coleman RL, Buzoianu M, et al. Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Investig N Drugs. 2013;31:77\u201384. https:\/\/doi.org\/10.1007\/s10637-012-9801-2.","journal-title":"Investig N Drugs"},{"key":"3533_CR104","doi-asserted-by":"crossref","unstructured":"Fontana E, Wang JS, Mckean M, Arkenau HT, Carter L, Galot R et al. EphA2-targeting bicycle toxin conjugate (BTC) BT5528 in patients (pts) with advanced solid tumors: a phase I\/II study. Ann Oncol. 2024;35:S511-2.","DOI":"10.1016\/j.annonc.2024.08.713"},{"key":"3533_CR105","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","volume":"30","author":"CE Brown","year":"2024","unstructured":"Brown CE, Hibbard JC, Alizadeh D, Blanchard MS, Natri HM, Wang D, et al. Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat Med. 2024;30:1001\u201312. https:\/\/doi.org\/10.1038\/s41591-024-02875-1.","journal-title":"Nat Med"},{"key":"3533_CR106","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.trecan.2018.09.004","volume":"4","author":"N Li","year":"2018","unstructured":"Li N, Gao W, Zhang YF, Ho M. Glypicans as cancer therapeutic targets. Trends Cancer. 2018;4:741\u201354. https:\/\/doi.org\/10.1016\/j.trecan.2018.09.004.","journal-title":"Trends Cancer"},{"key":"3533_CR107","doi-asserted-by":"publisher","first-page":"e004450","DOI":"10.1136\/jitc-2021-004450","volume":"10","author":"JB Foster","year":"2022","unstructured":"Foster JB, Griffin C, Rokita JL, Stern A, Brimley C, Rathi K, et al. Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors. J Immunother Cancer. 2022;10:e004450 https:\/\/doi.org\/10.1136\/jitc-2021-004450.","journal-title":"J Immunother Cancer"},{"key":"3533_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-00999-9","volume":"10","author":"CM Yde Ohki","year":"2020","unstructured":"Yde Ohki CM, Grossmann L, Alber E, Dwivedi T, Berger G, Werling AM, et al. The stress-Wnt-signaling axis: a hypothesis for attention-deficit hyperactivity disorder and therapy approaches. Transl Psychiatry. 2020;10:315. https:\/\/doi.org\/10.1038\/s41398-020-00999-9.","journal-title":"Transl Psychiatry"},{"key":"3533_CR109","doi-asserted-by":"publisher","first-page":"iii29","DOI":"10.1093\/noajnl\/vdad070.113","volume":"5","author":"J Taylor","year":"2023","unstructured":"Taylor J, Williamson J, Masih K, Bonner S, Lehner P, Gilbertson R. Plasma membrane profiling reveals a targetable cell-surface phenotype of Wnt-medulloblastoma. Neuro-Oncol Adv. 2023;5:iii29 https:\/\/doi.org\/10.1093\/noajnl\/vdad070.113.","journal-title":"Neuro-Oncol Adv"},{"key":"3533_CR110","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJMoa2210140","volume":"388","author":"M Gounder","year":"2023","unstructured":"Gounder M, Ratan R, Alcindor T, Sch\u00f6ffski P, van der Graaf WT, et al. Nirogacestat, a \u03b3-secretase inhibitor for desmoid tumors. N Engl J Med. 2023;388:898\u2013912. https:\/\/doi.org\/10.1056\/NEJMoa2210140.","journal-title":"N Engl J Med"},{"key":"3533_CR111","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s43018-020-0094-7","volume":"1","author":"L Tamayo-Orrego","year":"2020","unstructured":"Tamayo-Orrego L, Gallo D, Racicot F, Bemmo A, Mohan S, Ho B, et al. Sonic hedgehog accelerates DNA replication to cause replication stress promoting cancer initiation in medulloblastoma. Nat Cancer. 2020;1:840\u201354. https:\/\/doi.org\/10.1038\/s43018-020-0094-7.","journal-title":"Nat Cancer"},{"key":"3533_CR112","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00920-z","volume":"13","author":"LA Genovesi","year":"2021","unstructured":"Genovesi LA, Millar A, Tolson E, Singleton M, Hassall E, Kojic M, et al. Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma. Genome Med. 2021;13:103. https:\/\/doi.org\/10.1186\/s13073-021-00920-z.","journal-title":"Genome Med"},{"key":"3533_CR113","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-023-01185-4","volume":"15","author":"T Vo","year":"2023","unstructured":"Vo T, Balderson B, Jones K, Ni G, Crawford J, Millar A, et al. Spatial transcriptomic analysis of Sonic hedgehog medulloblastoma identifies that the loss of heterogeneity and promotion of differentiation underlies the response to CDK4\/6 inhibition. Genome Med. 2023;15:29. https:\/\/doi.org\/10.1186\/s13073-023-01185-4.","journal-title":"Genome Med"},{"key":"3533_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115629","volume":"226","author":"AD Pearson","year":"2025","unstructured":"Pearson AD, Chi S, Laetscht TW, Marshall L, Raetz E, George RE, et al. Paediatric strategy forum for medicinal product development of cyclin-dependent kinase inhibitors in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer. 2025;226:115629. https:\/\/doi.org\/10.1016\/j.ejca.2025.115629.","journal-title":"Eur J Cancer"},{"key":"3533_CR115","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1002\/cncr.34786","volume":"129","author":"KA Cole","year":"2023","unstructured":"Cole KA, Ijaz H, Surrey LF, Santi M, Liu X, Minard CG, et al. Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma. Cancer. 2023;129:2245\u201355. https:\/\/doi.org\/10.1002\/cncr.34786.","journal-title":"Cancer"},{"key":"3533_CR116","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1158\/1078-0432.CCR-23-2959","volume":"30","author":"SA Gatz","year":"2024","unstructured":"Gatz SA, Harttrampf AC, Brard C, Bautista F, Andr\u00e9 N, Abbou S, et al. Phase I\/II study of the WEE1 inhibitor adavosertib (AZD1775) in combination with carboplatin in children with advanced malignancies: arm C of the AcS\u00e9-ESMART trial. Clin Cancer Res. 2024;30:741\u201353. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2959.","journal-title":"Clin Cancer Res"},{"key":"3533_CR117","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aba7401","volume":"13","author":"R Endersby","year":"2021","unstructured":"Endersby R, Whitehouse J, Pribnow A, Kuchibhotla M, Hii H, Carline B, et al. Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma. Sci Transl Med. 2021;13:eaba7401. https:\/\/doi.org\/10.1126\/scitranslmed.aba7401.","journal-title":"Sci Transl Med"},{"key":"3533_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.633344","volume":"8","author":"J Buck","year":"2021","unstructured":"Buck J, Dyer PJC, Hii H, Carline B, Kuchibhotla M, Byrne J, et al. Veliparib Is an Effective Radiosensitizing Agent in a Preclinical Model of Medulloblastoma. Front Mol Biosci. 2021;8:633344. https:\/\/doi.org\/10.3389\/fmolb.2021.633344.","journal-title":"Front Mol Biosci"},{"key":"3533_CR119","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1158\/1078-0432.CCR-23-2094","volume":"30","author":"AD Staniszewska","year":"2024","unstructured":"Staniszewska AD, Pilger D, Gill SJ, Jamal K, Bohin N, Guzzetti S, et al. Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1. Clin Cancer Res. 2024;30:1338\u201351. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2094.","journal-title":"Clin Cancer Res"},{"key":"3533_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-84082-3","volume":"11","author":"M Buzzetti","year":"2021","unstructured":"Buzzetti M, Morlando S, Solomos D, Mehmood A, Cox AWI, Chiesa M, et al. Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells. Sci Rep. 2021;11:5374. https:\/\/doi.org\/10.1038\/s41598-021-84082-3.","journal-title":"Sci Rep"},{"key":"3533_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100038","volume":"1","author":"L Nobre","year":"2020","unstructured":"Nobre L, Zapotocky M, Khan S, Fukuoka K, Fonseca A, McKeown T, et al. Pattern of relapse and treatment response in WNT-activated medulloblastoma. Cell Rep Med. 2020;1:100038.","journal-title":"Cell Rep Med"},{"key":"3533_CR122","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/S1470-2045(13)70449-2","volume":"14","author":"V Ramaswamy","year":"2013","unstructured":"Ramaswamy V, Remke M, Bouffet E, Faria CC, Perreault S, Cho YJ, et al. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol. 2013;14:1200\u20137.","journal-title":"Lancet Oncol"},{"key":"3533_CR123","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1200\/JCO.20.01359","volume":"39","author":"R Kumar","year":"2021","unstructured":"Kumar R, Smith KS, Deng M, Terhune C, Robinson GW, Orr BA, et al. Clinical outcomes and patient-matched molecular composition of relapsed medulloblastoma. J Clin Oncol. 2021;39:807\u201321.","journal-title":"J Clin Oncol"},{"key":"3533_CR124","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1158\/1538-7445.AM2021-1291","volume":"81","author":"P Krzeminski","year":"2021","unstructured":"Krzeminski P, Lorena Gonz\u00e1lez-M\u00e9ndez L, San Segundo L, Mogoll\u00f3n P, Dia A, Hern\u00e1ndez-Garc\u00eda S, et al. The novel c-MYC inhibitor IDP-121 exhibits strong anti-myeloma effect. Cancer Res. 2021;81:1291.","journal-title":"Cancer Res"},{"key":"3533_CR125","doi-asserted-by":"crossref","unstructured":"Rodriguez-Rivera II, Wu TH, Ciotti R, Senapedis W, Sullivan K, Gao JZ, et al. A phase 1\/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma and other solid tumor types known for association with the MYC oncogene (MYCHELANGELO I). J Clin Oncol. 2023; 41(suppl 4; abstr TPS627).","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS627"},{"key":"3533_CR126","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1158\/1538-7445.AM2024-3297","volume":"84","author":"L Ma","year":"2024","unstructured":"Ma L, Tong Y, Yyang Z, Zhou O, Yan H, Xu R, et al. Discovery and evaluation of GT19870, a GSPT1\/Myc molecular glue drug (MGD) with oral bioavailability for targeting c-Myc and n-Myc-addictive blood cancer and solid tumors. Cancer Res. 2024;84:3297.","journal-title":"Cancer Res"},{"key":"3533_CR127","doi-asserted-by":"crossref","unstructured":"Ng SW, Gadde S, Wang Q, Cheung BB, Marshall GM. A novel small molecule inhibitor targeting MYC oncogenic signaling as an enhancer of HDAC inhibitors for the treatment of high-risk medulloblastoma. Cancer Res. 2024; 84 (6_Supplement): 4599.","DOI":"10.1158\/1538-7445.AM2024-4599"},{"key":"3533_CR128","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-12-18","volume":"12","author":"L Yuan","year":"2013","unstructured":"Yuan L, Zhang H, Liu J, Rubin JB, Cho YJ, Shu HK, et al. Growth factor receptor-Src-mediated suppression of GRK6 dysregulates CXCR4 signaling and promotes medulloblastoma migration. Mol Cancer. 2013;12:4599.","journal-title":"Mol Cancer"},{"key":"3533_CR129","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature11327","volume":"488","author":"PA Northcott","year":"2012","unstructured":"Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature. 2012;488:49\u201356.","journal-title":"Nature"},{"key":"3533_CR130","doi-asserted-by":"publisher","first-page":"E21","DOI":"10.1002\/ijc.26474","volume":"131","author":"J Bunt","year":"2012","unstructured":"Bunt J, Hasselt NE, Zwijnenburg DA, Hamdi M, Koster J, Versteeg R, et al. OTX2 directly activates cell cycle genes and inhibits differentiation in medulloblastoma cells. Int J Cancer. 2012;131:E21\u20133.","journal-title":"Int J Cancer"},{"key":"3533_CR131","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/2159-8290.CD-16-0844","volume":"7","author":"G Boulay","year":"2017","unstructured":"Boulay G, Awad ME, Riggi N, Archer TC, Iyer S, Boonseng WE, et al. OTX2 activity at distal regulatory elements shapes the chromatin landscape of group 3 medulloblastoma. Cancer Discov. 2017;7:288\u2013301.","journal-title":"Cancer Discov"},{"key":"3533_CR132","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/1878-0261.12177","volume":"12","author":"M Stromecki","year":"2018","unstructured":"Stromecki M, Tatari N, Morrison LC, Kaur R, Zagozewski J, Palidwor G, et al. Characterization of a novel OTX2-driven stem cell program in Group 3 and Group 4 medulloblastoma. Mol Oncol. 2018;12:495\u2013513.","journal-title":"Mol Oncol"},{"key":"3533_CR133","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17357-4","volume":"11","author":"J Zagozewski","year":"2020","unstructured":"Zagozewski J, Shahriary GM, Morrison LC, Saulnier O, Stromecki M, Fresnoza A, et al. An OTX2-PAX3 signaling axis regulates Group 3 medulloblastoma cell fate. Nat Commun. 2020;11:3627.","journal-title":"Nat Commun"},{"key":"3533_CR134","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00401-022-02505-5","volume":"144","author":"T Goschzik","year":"2022","unstructured":"Goschzik T, Mynarek M, Doerner E, Schenk A, Spier I, Warmuth-Metz M, et al. Genetic alterations of TP53 and OTX2 indicate increased risk of relapse in WNT medulloblastomas. Acta Neuropathol. 2022;144:1143\u201356.","journal-title":"Acta Neuropathol"},{"key":"3533_CR135","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/s41556-024-01460-5","volume":"26","author":"O Saulnier","year":"2024","unstructured":"Saulnier O, Zagozewski J, Liang L, Hendrikse LD, Layug P, Gordon V, et al. A group 3 medulloblastoma stem cell program is maintained by OTX2-mediated alternative splicing. Nat Cell Biol. 2024;26:1233\u201346.","journal-title":"Nat Cell Biol"},{"key":"3533_CR136","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1242\/dev.124.1.113","volume":"124","author":"R Mo","year":"1997","unstructured":"Mo R, Freer AM, Zinyk DL, Crackower MA, Michaud J, Heng HH, et al. Specific and redundant functions of Gli2 and Gli3 zinc finger genes in skeletal patterning and development. Development. 1997;124:113\u201323.","journal-title":"Development"},{"key":"3533_CR137","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1242\/dev.129.20.4753","volume":"129","author":"CB Bai","year":"2002","unstructured":"Bai CB, Auerbach W, Lee JS, Stephen D, Joyner AL. Gli2, but not Gli1, is required for initial Shh signaling and ectopic activation of the Shh pathway. Development. 2002;129:4753\u201361.","journal-title":"Development"},{"key":"3533_CR138","doi-asserted-by":"publisher","first-page":"14132","DOI":"10.1073\/pnas.0907134106","volume":"106","author":"JM Hyman","year":"2009","unstructured":"Hyman JM, Firestone AJ, Heine VM, Zhao Y, Ocasio CA, Han K, et al. Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade. Proc Natl Acad Sci USA. 2009;106:14132\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3533_CR139","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2009-09-241703","volume":"115","author":"A Merchant","year":"2010","unstructured":"Merchant A, Joseph G, Wang Q, Brennan S, Matsui W. Gli1 regulates the proliferation and differentiation of HSCs and myeloid progenitors. Blood. 2010;115:2391\u20136.","journal-title":"Blood"},{"key":"3533_CR140","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1095\/biolreprod.110.088997","volume":"84","author":"I Barsoum","year":"2011","unstructured":"Barsoum I, Yao HH. Redundant and differential roles of transcription factors Gli1 and Gli2 in the development of mouse fetal Leydig cells. Biol Reprod. 2011;84:894\u20139.","journal-title":"Biol Reprod"},{"key":"3533_CR141","first-page":"393","volume":"25","author":"M Kool","year":"2014","unstructured":"Kool M, Jones DT, J\u00e4ger N, Northcott PA, Pugh TJ, Hovestadt V, et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cell. 2014;25:393\u201340.","journal-title":"Cell"},{"key":"3533_CR142","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1038\/s41388-018-0249-5","volume":"37","author":"J Lu","year":"2018","unstructured":"Lu J, Liu L, Zheng M, Li X, Wu A, Wu Q, et al. MEKK2 and MEKK3 suppress Hedgehog pathway-dependent medulloblastoma by inhibiting GLI1 function. Oncogene. 2018;37:3864\u201378.","journal-title":"Oncogene"},{"key":"3533_CR143","first-page":"505","volume":"54","author":"L Antonucci","year":"2019","unstructured":"Antonucci L, Di Magno L, D\u2019Amico D, Manni S, Serrao SM, Di Pastena F, et al. Mitogen-activated kinase kinase kinase 1 inhibits hedgehog signaling and medulloblastoma growth through GLI1 phosphorylation. Int J Oncol. 2019;54:505\u201314.","journal-title":"Int J Oncol"},{"key":"3533_CR144","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.3390\/ijms21093126","volume":"21","author":"K Harada","year":"2020","unstructured":"Harada K, Ohashi R, Naito K, Kanki K. Hedgehog signal inhibitor GANT61 inhibits the malignant behavior of undifferentiated hepatocellular carcinoma cells by targeting non-canonical GLI signaling. Int J Mol Sci. 2020;21:3126.","journal-title":"Int J Mol Sci"},{"key":"3533_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106858","volume":"195","author":"L Maresca","year":"2023","unstructured":"Maresca L, Crivaro E, Migliorini F, Anichini G, Giammona A, Pepe S, et al. Targeting GLI1 and GLI2 with small molecule inhibitors to suppress GLI-dependent transcription and tumor growth. Pharm Res. 2023;195:106858.","journal-title":"Pharm Res"},{"key":"3533_CR146","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44352-2","volume":"15","author":"LH Zeng","year":"2024","unstructured":"Zeng LH, Tang C, Yao M, He Q, Qv M, Ren Q, et al. Phosphorylation of human glioma-associated oncogene 1 on Ser937 regulates Sonic Hedgehog signaling in medulloblastoma. Nat Commun. 2024;15:98.","journal-title":"Nat Commun"},{"key":"3533_CR147","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1242\/dev.125.14.2533","volume":"125","author":"Q Ding","year":"1998","unstructured":"Ding Q, Motoyama J, Gasca S, Mo R, Sasaki H, Rossant J, et al. Diminished Sonic hedgehog signaling and lack of floor plate differentiation in Gli2 mutant mice. Development. 1998;125:2533\u201343.","journal-title":"Development"},{"key":"3533_CR148","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1242\/dev.127.8.1593","volume":"127","author":"HL Park","year":"2000","unstructured":"Park HL, Bai C, Platt KA, Matise MP, Beeghly A, Hui CC, et al. Mouse Gli1 mutants are viable but have defects in SHH signaling in combination with a Gli2 mutation. Development. 2000;127:1593\u2013605.","journal-title":"Development"},{"key":"3533_CR149","doi-asserted-by":"publisher","first-page":"e0119834","DOI":"10.1371\/journal.pone.0119834","volume":"10","author":"Z Ahmad","year":"2015","unstructured":"Ahmad Z, Jasnos L, Gil V, Howell L, Hallsworth A, Petrie K, et al. Molecular and in vivo characterization of cancer-propagating cells derived from MYCN-dependent medulloblastoma. PLoS One. 2015;10:e0119834.","journal-title":"PLoS One"},{"key":"3533_CR150","doi-asserted-by":"publisher","first-page":"13726","DOI":"10.1073\/pnas.1610626113","volume":"113","author":"MW Richards","year":"2016","unstructured":"Richards MW, Burgess SG, Poon E, Carstensen A, Eilers M, Chesler L, et al. Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors. Proc Natl Acad Sci USA. 2016;113:13726\u20131373.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3533_CR151","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ccell.2019.10.001","volume":"36","author":"H Han","year":"2019","unstructured":"Han H, Jain AD, Truica MI, Izquierdo-Ferrer J, Anker JF, Lysy B, et al. Small-molecule MYC inhibitors suppress tumor growth and enhance immunotherapy. Cancer Cell. 2019;36:483\u201349.","journal-title":"Cancer Cell"},{"key":"3533_CR152","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.623679","volume":"10","author":"Z Liu","year":"2021","unstructured":"Liu Z, Chen SS, Clarke S, Veschi V, Thiele CJ. Targeting MYCN in pediatric and adult cancers. Front Oncol. 2021;10:623679.","journal-title":"Front Oncol"},{"key":"3533_CR153","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1158\/0008-5472.CAN-20-3108","volume":"81","author":"AJ Wolpaw","year":"2021","unstructured":"Wolpaw AJ, Bayliss R, B\u00fcchel G, Dang CV, Eilers M, Gustafson WC, et al. Drugging the \u201cundruggable\u201d MYCN oncogenic transcription factor: overcoming previous obstacles to impact childhood cancers. Cancer Res. 2021;81:1627\u201332.","journal-title":"Cancer Res"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03533-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03533-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03533-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:57:26Z","timestamp":1792166246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03533-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":153,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,11,5]]}},"alternative-id":["3533"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03533-8","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"13 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Claudia Montiel Equihua, Joseph Baxter, Itziar Areso, Geffen Lass and David Jenkinson, are employees of LifeArc. Andrew DJ Pearson is a consultant for LifeArc. All other authors have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}